FGF21 at physiological concentrations regulates vascular endothelial cell function through multiple pathways

Roth, 2020, Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study, J. Am. Coll. Cardiol., 76, 2982, 10.1016/j.jacc.2020.11.010 Gimbrone, 2016, Endothelial cell dysfunction and the pathobiology of atherosclerosis, Circ. Res., 118, 620, 10.1161/CIRCRESAHA.115.306301 Nishimura, 2000, Identification of a novel FGF, FGF-21, preferentially expressed in the liver, Biochim. Biophys. Acta, 1492, 203, 10.1016/S0167-4781(00)00067-1 Hill, 2020, FGF21 and the physiological regulation of macronutrient preference, Endocrinology, 161, 1, 10.1210/endocr/bqaa019 Fisher, 2016, Understanding the physiology of FGF21, Annu. Rev. Physiol., 78, 223, 10.1146/annurev-physiol-021115-105339 Tezze, 2019, FGF21 as modulator of metabolism in health and disease, Front. Physiol., 10, 419, 10.3389/fphys.2019.00419 Keuper, 2020, Circulating FGF21 levels in human health and metabolic disease, Exp. Clin. Endocrinol. Diabetes, 128, 752, 10.1055/a-0879-2968 Zhang, 2021, High-level serum fibroblast growth factor 21 concentration is closely associated with an increased risk of cardiovascular diseases: a systematic review and meta-analysis, Front. Cardiovasc. Med., 8 Fisher, 2010, Obesity is a fibroblast growth factor 21 (FGF21)-resistant state, Diabetes, 59, 2781, 10.2337/db10-0193 Villarroya, 2018, Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue, Aging Cell, 17, 10.1111/acel.12822 Redondo-Angulo, 2017, Fgf21 is required for cardiac remodeling in pregnancy, Cardiovasc. Res., 113, 1574, 10.1093/cvr/cvx088 Hanks, 2015, Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals, J. Clin. Transl. Endocrinol., 2, 77 Gälman, 2008, The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man, Cell Metab., 8, 169, 10.1016/j.cmet.2008.06.014 Geng, 2020, The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic, Nat. Rev. Endocrinol., 16, 654, 10.1038/s41574-020-0386-0 Staiger, 2017, Fibroblast growth factor 21-metabolic role in mice and men, Endocr. Rev., 38, 468, 10.1210/er.2017-00016 Huynh, 2019, Therapeutic targets for endothelial dysfunction in vascular diseases, Arch. Pharm. Res., 42, 848, 10.1007/s12272-019-01180-7 Xu, 2021, Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies, Pharmacol. Rev., 73, 924, 10.1124/pharmrev.120.000096 Yan, 2017, Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from H2O2-induced premature senescence through SIRT1, Am. J. Transl. Res., 9, 4492 Miller, 2002, Optimal gene expression analysis by microarrays, Cancer Cell, 2, 353, 10.1016/S1535-6108(02)00181-2 Ramoni, 2002, Cluster analysis of gene expression dynamics, Proc. Natl. Acad. Sci. U. S. A., 99, 9121, 10.1073/pnas.132656399 Xie, 2011, KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases, Nucleic Acids Res., 39, 10.1093/nar/gkr483 Biros, 2015, Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease, Oncotarget, 6, 12984, 10.18632/oncotarget.3848 Sabaratnam, 2018, Intact regulation of muscle expression and circulating levels of myokines in response to exercise in patients with type 2 diabetes, Physiol Rep, 6, 10.14814/phy2.13723 Sargeant, 2018, The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men, Appl. Physiol. Nutr. Metab., 43, 482, 10.1139/apnm-2017-0639 Slusher, 2015, Attenuated fibroblast growth factor 21 response to acute aerobic exercise in obese individuals, Nutr. Metab. Cardiovasc. Dis., 25, 839, 10.1016/j.numecd.2015.06.002 Talukdar, 2016, A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects, Cell Metab., 23, 427, 10.1016/j.cmet.2016.02.001 Gaich, 2013, The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes, Cell Metab., 18, 333, 10.1016/j.cmet.2013.08.005 Dong, 2015, Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study, Br. J. Clin. Pharmacol., 80, 1051, 10.1111/bcp.12676 Lewis, 2019, Going Back to the biology of FGF21: new insights, Trends Endocrinol. Metab., 30, 491, 10.1016/j.tem.2019.05.007 Incalza, 2018, Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases, Vasc. Pharmacol., 100, 10.1016/j.vph.2017.05.005 Wang, 2014, Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells, Cell. Physiol. Biochem., 34, 658, 10.1159/000363031 Huang, 2019, Fibroblast growth factor 21 enhances angiogenesis and wound healing of human brain microvascular endothelial cells by activating PPARγ, J. Pharmacol. Sci., 140, 120, 10.1016/j.jphs.2019.03.010 Li, 2017, FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway, Am. J. Transl. Res., 9, 5299 Guo, 2018, FGF21 protects human umbilical vein endothelial cells against high glucose-induced apoptosis via PI3K/Akt/Fox3a signaling pathway, J. Diabetes Complicat., 32, 729, 10.1016/j.jdiacomp.2018.05.012 Chen, 2018, FGF21 protects the blood-brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury, J. Neurotrauma, 35, 2091, 10.1089/neu.2017.5271 Zhu, 2014, Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo, Can. J. Physiol. Pharmacol., 92, 927, 10.1139/cjpp-2014-0227 Yao, 2021, FGF21 attenuates hypoxiainduced dysfunction and inflammation in HPAECs via the microRNA27bmediated PPARgamma pathway, Int. J. Mol. Med., 47, 116, 10.3892/ijmm.2021.4949 Wang, 2019, FGF21 protects against hypoxia injury through inducing HSP72 in cerebral microvascular endothelial cells, Front. Pharmacol., 10, 101, 10.3389/fphar.2019.00101 Chen, 2020, Inhibition of the ox-LDL-induced pyroptosis by FGF21 of human umbilical vein endothelial cells through the TET2-UQCRC1-ROS pathway, DNA Cell Biol., 39, 661, 10.1089/dna.2019.5151 Chen, 2018, FGF21 attenuates hypoxia-induced dysfunction and apoptosis in HPAECs through alleviating endoplasmic reticulum stress, Int. J. Mol. Med., 42, 1684 Kim, 2019, Prenylated Rab acceptor RABAC1 inhibits anti-apoptotic protein BCL2A1 and induces apoptosis, Biochem. Biophys. Res. Commun., 513, 940, 10.1016/j.bbrc.2019.04.080 Tan, 2021, Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma, Theranostics, 11, 1364, 10.7150/thno.51725 Liang, 2021, The stress-inducible BCL2A1 is required for ovarian cancer metastatic progression in the peritoneal microenvironment, Cancers (Basel), 13, 4577, 10.3390/cancers13184577 Kalliolias, 2016, TNF biology, pathogenic mechanisms and emerging therapeutic strategies, Nat. Rev. Rheumatol., 12, 49, 10.1038/nrrheum.2015.169 Matsumoto, 2020, Ensemble structural analyses depict the regulatory mechanism of non-phosphorylated human MAP2K4, Biochem. Biophys. Res. Commun., 521, 106, 10.1016/j.bbrc.2019.10.086 Torraco, 2021, Novel NDUFA12 variants are associated with isolated complex I defect and variable clinical manifestation, Hum. Mutat., 42, 699, 10.1002/humu.24195 Fan, 2022, PERK, beyond an unfolded protein response sensor in estrogen-induced apoptosis in endocrine-resistant breast cancer, Mol. Cancer Res., 20, 193, 10.1158/1541-7786.MCR-21-0702 Zhang, 2021, Ndufa6 regulates adipogenic differentiation via Scd1, Adipocyte, 10, 646, 10.1080/21623945.2021.2007590 Raghubeer, 2021, Methylenetetrahydrofolate (MTHFR), the one-carbon cycle, and cardiovascular risks, Nutrients, 13, 4562, 10.3390/nu13124562 Kim, 2020, ACOX3 dysfunction as a potential cause of recurrent spontaneous vasospasm of internal carotid artery, Transl. Stroke Res., 11, 1041, 10.1007/s12975-020-00779-z Drzewiecka, 2020, Altered expression of 17betahydroxysteroid dehydrogenase type 2 and its prognostic significance in nonsmall cell lung cancer, Int. J. Oncol., 56, 1352 Gao, 2019, Functional silencing of HSD17B2 in prostate cancer promotes disease progression, Clin. Cancer Res., 25, 1291, 10.1158/1078-0432.CCR-18-2392 Li, 2020, Comprehensive analysis of ATP6V1s family members in renal clear cell carcinoma with prognostic values, Front. Oncol., 10 Vaz, 2019, Mutations in PCYT2 disrupt etherlipid biosynthesis and cause a complex hereditary spastic paraplegia, Brain, 142, 3382, 10.1093/brain/awz291 Fullerton, 2010, Complementation of the metabolic defect in CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)-deficient primary hepatocytes, Metabolism, 59, 1691, 10.1016/j.metabol.2010.03.022 Onouchi, 2008, ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms, Nat. Genet., 40, 35, 10.1038/ng.2007.59 Bhattarai, 2021, Association of ITPKC gene polymorphisms rs28493229 and rs2290692 in north indian children with Kawasaki disease, Pediatr. Res. Leon-Del-Rio, 2017, Holocarboxylase synthetase: a moonlighting transcriptional coregulator of gene expression and a cytosolic regulator of biotin utilization, Annu. Rev. Nutr., 37, 207, 10.1146/annurev-nutr-042617-104653 Zempleni, 2014, Novel roles of holocarboxylase synthetase in gene regulation and intermediary metabolism, Nutr. Rev., 72, 369, 10.1111/nure.12103 Chang, 2014, SIRT1 and other sirtuins in metabolism, Trends Endocrinol. Metab., 25, 138, 10.1016/j.tem.2013.12.001 Winnik, 2015, Protective effects of sirtuins in cardiovascular diseases: from bench to bedside, Eur. Heart J., 36, 3404, 10.1093/eurheartj/ehv290 Kauppinen, 2013, Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders, Cell. Signal., 25, 1939, 10.1016/j.cellsig.2013.06.007